as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹2,325.7
Change
-54.3 (-2.28%)
Open
₹2,380.0
Prev. Close
₹2,380.0
Day High
₹2,392.5
Day Low
₹2,307.3
Volume Analysis
Traded
985,878
Delivered
528,698
Delivery %
53.63%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (23.6%)
- •Strong operating margin (27.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (66.1%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,461.56 | ₹2,427.03 | ₹2,376.36 | ₹2,341.83 | ₹2,291.16 | ₹2,256.63 | ₹2,205.96 |
| Fibonacci | ₹2,427.03 | ₹2,394.48 | ₹2,374.38 | ₹2,341.83 | ₹2,309.28 | ₹2,289.18 | ₹2,256.63 |
| Camarilla | ₹2,349.13 | ₹2,341.32 | ₹2,333.51 | ₹2,341.83 | ₹2,317.89 | ₹2,310.08 | ₹2,302.27 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+14.78%
1 Week
-5.51%
1 Month
-7.53%
3 Months
+7.58%
6 Months
+11.18%
1 Year
+18.77%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹635.56
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.29%
Net margin 10.14% × asset turnover 0.85x × equity multiplier 1.89x
Company Overview
Sector
Healthcare
Market Cap
₹69,000 Cr
P/E (TTM)
22.1
ROE
23.6%
Book Value
₹372.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Glenmark Pharmaceuticals holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 75/100. The strongest factor is Financial Strength (100/100), while Valuation (34/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (23.6%); strong operating margin (27.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
75/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has delivered good profit growth of 19.4% CAGR over last 5 years
- −The company has delivered a poor sales growth of 9.19% over past five years.
- −Company has a low return on equity of -3.28% over last 3 years.
- −Debtor days have increased from 85.2 to 107 days.
- −Working capital days have increased from 41.2 days to 80.5 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Glenmark received USFDA EIR for Goa facility on September 23, 2026, with VAI status.
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings
Glenmark held its 48th AGM on Sept. 11, 2026; shareholders approved Rs. 2.50 dividend and reappointed Blanche Saldanha.
Glenmark launches RYALTRIS nasal spray in Brazil after ANVISA approval.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses + | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating Profit | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 14.0% | 14.0% | -8.0% | 16.0% | 18.0% | 18.0% | 18.0% | 17.0% | 18.0% | 39.0% | 22.0% | 20.0% | 20.0% |
| Other Income + | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | -14.0% | 997.0% | -18.0% | 319.0% | 26.0% | 25.0% | 24.0% | 45.0% | 51.0% | 37.0% | 24.0% | 22.0% | 25.0% |
| Net Profit + | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | 5 | -3 | -12 | -43 | 12 | 13 | 12 | 0 | 2 | 22 | 14 | 11 | 17 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,737 |
| Expenses + | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,970 | 12,410 | 12,940 |
| Operating Profit | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 4,797 |
| OPM % | 18.0% | 19.0% | 22.0% | 18.0% | 16.0% | 16.0% | 19.0% | 19.0% | 14.0% | 10.0% | 18.0% | 27.0% | 27.0% |
| Other Income + | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1,805 | -1,443 |
| Interest | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| Profit before tax | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,399 | 1,985 | 2,533 |
| Tax % | 61.0% | 29.0% | 26.0% | 28.0% | 29.0% | 29.0% | 30.0% | 31.0% | 47.0% | 430.0% | 25.0% | 31.0% | — |
| Net Profit + | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS in Rs | 8 | 26 | 39 | 28 | 33 | 28 | 34 | 33 | 11 | -53 | 37 | 48 | 64 |
| Dividend Payout % | 26.0% | 8.0% | 5.0% | 7.0% | 6.0% | 9.0% | 7.0% | 7.0% | 24.0% | -5.0% | 7.0% | 10.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 10,484 |
| Borrowings + | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 | 594 |
| Other Liabilities + | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 | 8,801 |
| Total Liabilities | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
| Fixed Assets + | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 |
| CWIP | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 | 909 |
| Investments | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets + | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 | 13,041 |
| Total Assets | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
| Equity Capital | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 |
| Cash from Investing Activity + | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | 58 | -1,237 |
| Cash from Financing Activity + | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| Net Cash Flow | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| CFO/OP | 66 | 57 | 67 | 124 | 111 | 109 | 79 | 72 | 77 | 65 | -6 | 92 |
| Free Cash Flow | -56 | -544 | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1,162 | -1,576 | 2,090 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 18.21% | 18.7% | 18.58% | 18.42% | 17.06% | 15.96% | 15.56% | 15.05% | 13.97% | 14.02% | 13.7% | 13.81% |
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.64% | 46.64% | 46.65% | 46.65% | 46.65% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| FII | 24.79% | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.15% | 20.62% | 20.73% | 19.2% | 20.35% | 20.89% |
| DII | 10.31% | 10.92% | 13.36% | 13.93% | 13.21% | 13.85% | 14.6% | 17.64% | 18.61% | 20.09% | 19.28% | 18.6% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Glenmark Pharmaceuticals (this stock) | 69,000 | 22.1 | 6.56 | 23.6% |
| Fortis Healthcare Ltd | 66,565 | 62.4 | 6.71 | 11.2% |
| Aster Dm Quality Care Ltd | 66,312 | 184.0 | 9.38 | 11.3% |
| Alkem Laboratories Ltd. | 63,680 | 28.0 | 4.61 | 18.9% |
| Biocon Limited. | 61,298 | 84.3 | 1.79 | 1.4% |
| Ipca Laboratories Ltd | 50,650 | 36.9 | 6.28 | 15.7% |
| Anthem Biosciences Ltd | 49,633 | 83.6 | 16.25 | 22.3% |
Which Mutual Funds Hold Glenmark Pharmaceuticals?
Frequently Asked Questions about Glenmark Pharmaceuticals
Glenmark Pharmaceuticals (GLENMARK) closed at ₹2,325.7 on NSE on 28 September 2026, down 54.3 (2.28%) from the previous close.
Glenmark Pharmaceuticals trades on the NSE (National Stock Exchange of India) under the symbol GLENMARK.
Glenmark Pharmaceuticals has a trailing twelve-month P/E (price-to-earnings) ratio of 22.1.
Glenmark Pharmaceuticals has a dividend yield of 0.21%.
Glenmark Pharmaceuticals's 52-week high is ₹2,538.0 and its 52-week low is ₹1,793.0.
Glenmark Pharmaceuticals has a market capitalisation of ₹69,000 crore.
Glenmark Pharmaceuticals has a TopFund Quality Score of 75/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Glenmark Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.